Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it’s here today and CRSPR Therapeutics AG (NASDAQ: CRSP) is leading the way.
[content-module:CompanyOverview|NASDAQ:CRSP]In late 2023, the company had a breakthrough when it received approval for CASGEVY. This is the first gene editing treatment of its kind to be approved. CASGEVY addresses sickle cell disease (SCD) and beta-thalassemia.
